GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » EBIT

CRDF (Cardiff Oncology) EBIT : $-48.65 Mil (TTM As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology EBIT?

Cardiff Oncology's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was $-12.57 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was $-48.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cardiff Oncology's annualized ROC % for the quarter that ended in Dec. 2024 was -848.31%. Cardiff Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -2,304.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cardiff Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -26.18%.


Cardiff Oncology EBIT Historical Data

The historical data trend for Cardiff Oncology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology EBIT Chart

Cardiff Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.31 -28.86 -39.90 -45.41 -48.65

Cardiff Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.33 -10.93 -12.55 -12.60 -12.57

Competitive Comparison of Cardiff Oncology's EBIT

For the Biotechnology subindustry, Cardiff Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's EV-to-EBIT falls into.



Cardiff Oncology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology  (NAS:CRDF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cardiff Oncology's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-50.288 * ( 1 - 0% )/( (6.264 + 5.592)/ 2 )
=-50.288/5.928
=-848.31 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cardiff Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-50.288/( ( (2.297 + max(-10.153, 0)) + (2.067 + max(-9.41, 0)) )/ 2 )
=-50.288/( ( 2.297 + 2.067 )/ 2 )
=-50.288/2.182
=-2,304.67 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.618 + 0 + 1.047) - (9.825 + 0 + 1.993)
=-10.153

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.773 + 0 + 2.535) - (9.972 + 0 + 2.746)
=-9.41

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cardiff Oncology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-48.651/185.853
=-26.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology EBIT Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Executives
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116